FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer By Ogkologos - November 20, 2024 793 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the INAVO120 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Breast Cancer Patient Given 2 Years to Live is Now a... May 28, 2021 FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate... April 15, 2022 Whole-Genome Sequencing Provides Rapid and Accurate Genomic Profiling in Patients with... March 11, 2021 Researchers Develop a Potential “Universal” CAR T-Cell Therapy for Blood Cancers September 27, 2023 Load more HOT NEWS Wine Racks and the Mystery of Survival FDA Approves Zidesamtinib for ROS1-positive Non-Small Cell Lung Cancer New on NCI Websites for June 2018 Pembrolizumab Plus Chemoradiotherapy Significantly Improves OS in Patients with Locally Advanced...
